MASI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Masimo Corp (MASI) is not a strong buy at the moment for a long-term beginner investor with $50,000-$100,000 available. While the company has promising growth prospects and positive analyst sentiment, its recent financial performance and technical indicators suggest caution. The stock is better suited for monitoring rather than immediate investment.
The technical indicators for MASI are bearish. The MACD histogram is negative and expanding, RSI is neutral at 34.188, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 136.189, with key support at 131.674 and resistance at 140.705.
Analysts have raised price targets recently, with Wells Fargo and BTIG highlighting confidence in the company's multi-year growth trajectory and innovation in MedTech. Revenue is expected to grow at a 7%-10% CAGR through 2028.
The company's Q3 2025 financials show a significant drop in net income (-1124.49% YoY) and EPS (-1133.33% YoY), indicating profitability challenges. Additionally, there is no recent news or congress trading data to provide further positive sentiment.
In Q3 2025, Masimo's revenue increased by 8.21% YoY to $371.5M, and gross margin improved slightly to 62.07%. However, net income dropped significantly to -$100.4M, and EPS fell to -1.86, reflecting major profitability issues.
Analysts are generally positive on MASI. Wells Fargo raised the price target to $190, and BTIG raised it to $200, both maintaining bullish ratings. BofA initiated coverage with a Neutral rating and a $162 price target. Analysts are optimistic about the company's innovation and long-term growth potential.
